参考文献/References:
[1].Hindricks G,Potpara T,Dagres N,et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS) :the task force for the diagnosis and management of atrial fibrillation of the european society of cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC [J]. Eur Heart J,2021,42(5):373-498.
[2].Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[3].Farmakis D,Parissis J,Filippatos G. Insights into onco-cardiology:atrial fibrillation in cancer[J]. J Am Coll Cardiol,2014,63(10):945-953.
[4].Saliba W,Rennert HS,Gronich N,et al. Association of atrial fibrillation and cancer:analysis from two large population-based case-control studies[J]. PLoS One,2018,13(1):e0190324.
[5].D’Souza M,Smedegaard L,Madelaire C,et al. Incidence of atrial fibrillation in conjunction with breast cancer[J]. Heart Rhythm,2019,16(3):343-348.
[6].Guha A,Fradley MG,Dent SF,et al. Incidence,risk factors,and mortality of atrial fibrillation in breast cancer:a SEER-Medicare analysis[J]. Eur Heart J,2022,43(4):300-312.
[7].Krijthe BP,Kunst A,Benjamin EJ,et al. Projections on the number of individuals with atrial fibrillation in the European Union,from 2000 to 2060[J]. Eur Heart J,2013,34(35):2746-2751.
[8].曾军,曹丽娟,汪成,等.基于单中心的乳腺癌合并心房颤动患病率调查[J].中国临床医学,2021,28(2):169-172.
[9].Lei S,Zheng R,Zhang S,et al. Global patterns of breast cancer incidence and mortality:a population-based cancer registry data analysis from 2000 to 2020 [J]. Cancer Commun (Lond),2021,41(11):1183-1194.
[10].Chan DSM,Abar L,Cariolou M,et al. World Cancer Research Fund International:Continuous Update Project-systematic literature review and meta-analysis of observational cohort studies on physical activity,sedentary behavior,adiposity,and weight change and breast cancer risk[J]. Cancer Causes Control,2019,30(11):1183-1200.
[11].Rogers PA,Bernard ML,Madias C,et al. Current evidence-based understanding of the epidemiology ,prevention,and treatment of atrial fibrillation[J]. Curr Probl Cardiol,2018,43(6):241-283.
[12].Mahajan R,Lau DH,Brooks AG,et al. Atrial fibrillation and obesity:reverse remodeling of atrial substrate with weight reduction[J]. JACC Clin Electrophysiol,2021,7(5):630-641.
[13].Ershaid N,Sharon Y,Doron H,et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun,2019,10(1):4375.
[14].Ajoolabady A,Nattel S,Lip GYH,et al. Inflammasome signaling in atrial?fibrillation:JACC State-of-the-Art Review[J]. J Am Coll Cardiol,2022,79(23):2349-2366.
[15].Yoo S,Pfenniger A,Hoffman J,et al. Attenuation of oxidative injury with targeted expression of NADPH oxidase 2 short hairpin rna prevents onset and maintenance of electrical remodeling in the canine atrium:a novel gene therapy approach to atrial fibrillation[J]. Circulation,2020,142(13):1261-1278.
[16].Chen PS,Chen LS,Fishbein MC,et al. Role of the autonomic nervous system in atrial fibrillation:pathophysiology and therapy[J]. Circ Res,2014,114(9):1500-1515.
[17].Guzzetti S,Costantino G,Vernocchi A,et al. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation[J]. Intern Emerg Med,2008,3(3):227-231.
[18].吕海辰,夏云龙.发展中的肿瘤心脏病学[J].中国医刊,2019,54(08):816-819+2.
[19].Alexandre J,Moslehi JJ,Bersell KR,et al. Anticancer drug-induced cardiac rhythm disorders:Current knowledge and basic underlying mechanisms[J]. Pharmacol Ther,2018,189:89-103.
[20].Iqubal A,Iqubal MK,Sharma S,et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity:old drug with a new vision[J]. Life Sci,2019,218:112-131.
[21].Keramida K,Filippatos G,Farmakis D. Cancer treatment and atrial fibrillation:use of pharmacovigilance databases to detect cardiotoxicity[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(4):321-323.
[22].Menichelli D,Vicario T,Ameri P,et al. Cancer and atrial fibrillation:epidemiology,mechanisms,and anticoagulation treatment[J]. Prog Cardiovasc Dis,2021,66:28-36.
[23].Yuan M,Tse G,Zhang Z,et al. The incidence of atrial fibrillation with trastuzumab treatment:a systematic review and meta-analysis [J]. Cardiovasc Ther,2018,36(6):e12475.
[24].ElZarrad MK,Mukhopadhyay P,Mohan N,et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice[J]. PLoS One,2013,8(11):e79543.
[25].Herrmann J. Adverse cardiac effects of cancer therapies:cardiotoxicity and arrhythmia[J]. Nat Rev Cardiol,2020,17(8):474-502.
[26].Chokesuwattanaskul R,Chiengthong K,Thongprayoon C,et al. Nonsteroidal anti-inflammatory drugs and incidence of atrial fibrillation:a meta-analysis[J]. QJM,2020,113(2):79-85.
[27].Lee CW,Muo CH,Liang JA,et al. Atrial fibrillation is associated with morphine treatment in female breast cancer patients:a retrospective Population-Based Time-Dependent Cohort Study [J]. Medicine (Baltimore),2016,95(11):e3102.
[28].January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol,2019,74(1):104-132.
[29].Lyon AR,López-Fernández T,Couch LS,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA),the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)[J]. Eur Heart J,2022,43(41):4229-4361.
[30].Connolly SJ,Karthikeyan G,Ntsekhe M,et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation[J]. N Engl J Med,2022,387(11):978-988.
[31].Fanola CL,Ruff CT,Murphy SA,et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation:analysis of the ENGAGE AF -TIMI 48 Trial[J]. J Am Heart Assoc,2018,7(16):e008987.
[32].Melloni C,Dunning A,Granger CB,et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer :insights from the ARISTOTLE Trial [J]. Am J Med,2017,130(12):1440-1448.
[33].Chen ST,Hellkamp AS,Becker RC,et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer:observations from ROCKET AF[J]. Eur Heart J Qual Care Clin Outcomes,2019,5(2):145-152.
[34].Connolly SJ,Ezekowitz MD,Yusuf S,et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139-1151.
[35].Mulder FI,van Es N,Kraaijpoel N,et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer:Results from the Hokusai VTE Cancer study[J]. Thromb Res,2020,185:13-19.
[36].Agnelli G,Becattini C,Meyer G,et al. Apixaban for the treatment of venous thromboembolism associated with cancer [J]. N Engl J Med,2020,382(17):1599-1607.
[37].Planquette B,Bertoletti L,Charles-Nelson A,et al. Rivaroxaban vs?Dalteparin in Cancer-Associated Thromboembolism:A Randomized Trial[J]. Chest,2022,161(3):781-790.
[38].Pacholczak-Madej R,Bazan-Socha S,Zar?ba L,et al. Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy:a cohort study [J]. Int J Cardiol,2021,324:78-83.
[39].Sánchez-Fuentes A,Rivera-Caravaca JM,López-Gálvez R,et al. Non-vitamin K antagonist oral anticoagulants and drug-food interactions:implications for clinical practice and potential role of probiotics and prebiotics[J]. Front Cardiovasc Med,2022,8:787235.
[40].Olesen KKW,Wheeler M,Eikelboom JW. Oral anticoagulant treatment in patients with atrial fibrillation and cancer[J]. Thromb Haemost,2020,120(2):194-196.
[41].Musgrave KM,Power K,Laffan M,et al. Practical treatment guidance for cancer-associated thrombosis - Managing the challenging patient:a consensus statement [J]. Crit Rev Oncol Hematol,2022,171:103599.
[42].Steffel J,Verhamme P,Potpara TS,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Eur Heart J,2018,39(16):1330-1393.
[43].Lee SR,Choi EK,Kwon S,et al. Oral anticoagulation in asian patients with atrial fibrillation and a history of intracranial hemorrhage[J]. Stroke,2020,51(2):416-423.
[44].Jagsi R,Griffith KA,Koelling T,et al. Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer[J]. J Clin Oncol,2006,24(18):2779-2785.
[45].Barber M,Nguyen LS,Wassermann J,et al. Cardiac arrhythmia considerations of hormone cancer therapies[J]. Cardiovasc Res,2019,115(5):878-894.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(8):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(8):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(8):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(8):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]郭良 黄鹤.恶性肿瘤相关心房颤动发病机制的研究进展[J].心血管病学进展,2022,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
GUO LiangHUANG He.Pathogenesis of Malignant Tumor-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(8):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]